Stocks and Investing Stocks and Investing
Thu, October 25, 2018

Christopher Raymond Maintained (VRTX) at Buy with Decreased Target to $201 on, Oct 25th, 2018


Published on 2024-10-26 09:53:29 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Raymond James, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $211 to $201 on, Oct 25th, 2018.

Christopher has made no other calls on VRTX in the last 4 months.



There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018


These are the ratings of the 2 analyists that currently disagree with Christopher


  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $206 on, Monday, July 30th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018

Contributing Sources